Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Pyridinolcarbamate

Known as: Pyricarbate, Pyridinolcarbamate [Chemical/Ingredient], 2,6-Pyridinedimethanol-bis-(N-methylcarbamate) 
A drug that has been given by mouth in the treatment of atherosclerosis and other vascular disorders, hyperlipidemias, and thrombo-embolic disorders… Expand
National Institutes of Health

Related topics

Related topics

14 relations

Narrower (5)

AngininAngioxineP-23Parmidine
Expand

Broader (1)

Hypolipidemic Agents
In BloodNitroglycerinagonistsanalogs & derivatives
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1988
1988
Metabolic changes in the arterial wall and endothelial injury in experimental methioninaemia.
Chronic administration of methionine to rats induced endothelial lesion manifested by increased endothelaemia and metabolic… Expand
Is this relevant?
1983
1983
Anti-proliferative effect of pyridinolcarbamate and of aspirin in the early stages of atherogenesis in swine.
When young swine are fed a suitable hyperlipidemic (HL) diet the number of cells in intimal cell masses (ICM) of large and medium… Expand
Is this relevant?
1980
1980
Lack of effect of phenformin, pyridinolcarbamate combined with a decalcifying agent, and an onion--garlic mixture on growth and necrosis of aortic atherosclerosis in ballooned swine.
  • W. M. Lee, K. Lee
  • Experimental and molecular pathology
  • 1980
    • Corpus ID: 27735062
Abstract This was a study of the effect of three agents (phenformin, pyridinolcarbamate combined with a decalcifying agent, and… Expand
Is this relevant?
1977
1977
Diabetic microangiopathy in KK mice. II. Suppression of Glomerulosclerosis by pyridinolcarbamate.
Abstract KK mice with genetic diabetic glomerulosclerosis were treated with 250 mg/kg of pyridinolcarbamate (PDC), an… Expand
Is this relevant?
1976
1976
Hyperacute renal allograft rejection in the primate. Therapeutic limitations of antiplatelet agents alone and combined with heparin.
Two antiplatelet drugs, pyridinolcarbamate and Sudoxicam, were tested separately and in combination with heparin for their… Expand
Is this relevant?
1973
1973
Effect of histamine, bradykinin and morphine on adrenaline release from rat adrenal gland.
  • T. Yoshizaki
  • Japanese journal of pharmacology
  • 1973
    • Corpus ID: 31236355
Abstract Effects of histamine, bradykinin and morphine on adrenaline secretion from rat adrenal gland were investigated by means… Expand
Is this relevant?
1973
1973
A clinical trial with pyridinolcarbamate in the treatment of patients with obstructive diseases of the peripheral arteries.
Treatment with pyridinolcarbamate for obstructive diseases of the peripheral arteries could be evaluated in 21 patients. The… Expand
Is this relevant?
1972
1972
Metabolic effect of pyridinolcarbamate on the vascular wall of rats with hypervitaminosis D.
Abstract Pyridinolcarbamate (PDC) was administered in daily doses of 25 mg/kg for 3 or 9 weeks to rats with experimentally… Expand
Is this relevant?
1970
1970
Clinical pharmacologic evaluation of the antiatherosclerotic agent, pyridinolcarbamate. A double-blind crossover trial in the treatment of atherosclerosis obliterans.
The antiatherosclerotic effect of pyridinolcarbamate in man has been subjected to the present controlled clinical trial in 43… Expand
Is this relevant?
1966
1966
Atherosclerosis-inhibiting effect of an antibradykinin agent, pyridinolcarbamate.
Abstract An antibradykinin and antilysylbradykinin agent, pyridinolcarbamate (2,6-bis-hydroxymethylpyridine- bis N… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE